Patrice Sarrazin, Senior Scientific Evaluator, In Vitro Diagnostic Devices, Health Canada
M. Sarrazin addresses the common mistakes made by biomarker developers and reveals what they should know from a regulatory point of view.
Dx2010 Markers to Market brought together leading international researchers, regulatory representatives and entrepreneurs from the diagnostics sector to examine regulatory hurdles and commercialization challenges on the path from biomarker discovery to market for molecular diagnostics and prognostics. Dx2010 Markers to Market was co-hosted by the Ontario Genomics Institute and MaRS.
MaRS - Building Canada’s next generation of global technology companies. marsdd.com